PAC Partners initiates analyst coverage on Anatara Lifesciences

This month PAC Partners initiated analyst coverage on Anatara Lifesciences.

PAC has initiated coverage with a Buy rating and price target of $1.36/share.

To download the full report, please click here.

NEW Wilsons Research & Valuation Report

NEW Wilsons Research & Valuation Report

Wilsons Equity Research has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a BUY rating and a price target of $1.66 per share.

Still have our nose in this little trough

Please open the attached PDF to view the report.

NDF Research Research & Valuation Report

NDF Research’s Initiation of Coverage Research & Valuation Report

NDF Research has released its first research and valuation report on Anatara Lifesciences (ANR). The report valued Anatara at $2.22 base case and $5.94 optimistic case using a DCF approach, with a target price of $4.00 sitting at around the midpoint of the valuation range.

Please click here to view the report.

Anatara Lifesciences features in Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy Class B recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please click here to view the article.

NEW Wilson HTM Research & Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and price target of $1.75 per share.

Please open the attached PDF to view the report.

NEW Wilson HTM Research and Valuation Report

Wilson HTM has released its latest research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a new price target of $1.75 per share.

Please open the attached PDF to view the report.

NEW Wilson HTM Anatara Research & Valuation Report

Wilson HTM has released its fourth research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and increased price target of $1.82 per share.

Please open the attached PDF to view the report.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM has released its third research and valuation report on Anatara Lifesciences (ANR). The report maintained a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Anatara features in the latest edition of Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Bioshares delivers independent investment research to investors on Australian biotech, pharma and healthcare companies.

Please open the attached PDF to view the report.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM has released its second research and valuation report on Anatara Lifesciences (ANR). The report provided a Speculative BUY rating and a price target at $1.18 per share.

Please open the attached PDF to view the report.

Anatara features in the latest edition of Bioshares

Bioshares has featured Anatara Lifesciences (ANR) in its latest edition. The article provided a Speculative Buy recommendation.

Please open the attached PDF to view the report.

Wilson HTM – ANR Research & Valuation Report

Wilson HTM today released a research and valuation report on Anatara Lifesciences (ANR). The report initiated a Speculative BUY rating and a price target of 60 cps.

Bull case valuations can push north of $2.50 per share if project success and international marketing partners are delivered over the next few years.”

Please open the attached PDF to view the report.